PT  - JOURNAL ARTICLE
AU  - Niamh Boyle
AU  - Marissa O'Callaghan
AU  - Ali Ataya
AU  - Nishant Gupta
AU  - Michael P. Keane
AU  - David J. Murphy
AU  - Cormac McCarthy
TI  - Pulmonary renal syndrome: a clinical review
AID  - 10.1183/20734735.0208-2022
DP  - 2022 Dec 01
TA  - Breathe
PG  - 220208
VI  - 18
IP  - 4
4099  - http://breathe.ersjournals.com/content/18/4/220208.short
4100  - http://breathe.ersjournals.com/content/18/4/220208.full
SO  - Breathe2022 Dec 01; 18
AB  - The term “pulmonary renal syndrome” describes a clinical syndrome which is characterised by the presence of both diffuse alveolar haemorrhage and glomerulonephritis. It encompasses a group of diseases with distinctive clinical and radiological manifestations, as well as different pathophysiological processes. The most common diseases implicated are anti-neutrophil cytoplasm antibodies (ANCA)-positive small vessel vasculitis and anti-glomerular basement membrane (anti-GBM) disease. Prompt recognition is required as respiratory failure and end-stage renal failure can rapidly occur. Treatment includes a combination of glucocorticoids, immunosuppression, plasmapheresis and supportive measures. The use of targeted treatments has significantly reduced mortality. Thus, an understanding of pulmonary renal syndrome is essential for the respiratory physician.Pulmonary renal syndrome is the combination of rapidly progressive glomerulonephritis (RPGN) and diffuse alveolar haemorrhage (DAH). Morbidity and mortality are high so prompt diagnosis and intervention are key for the respiratory physician. https://bit.ly/3UFAmR9